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Resumen
El interés en la toma de decisión médica 
compartida y en las ayudas a la toma de de-
cisión se desarrollaron en los años ochenta y 
noventa con un foco inicial en pacientes con 
cáncer, y en particular, en mujeres con cáncer 
de mama. Este interés con el tiempo ha experi-
mentado un cambio en énfasis desde la curio-
sidad acerca del signifi cado de estos conceptos 
y su potencial para mejorar la participación 
del paciente en la toma de decisión a una pro-
moción a gran escala, intentos de expansión, 
implementación en una variedad de situaciones 
clínicas, medición de resultados múltiples en 
niveles clínicos y de política pública y el desa-
rrollo de criterios estandarizados para evaluar 
las ayudas a la toma de decisión. En este artí-
culo planteamos la cuestión: ¿estamos movién-
donos demasiado rápido en la promoción de la 
decisión médica compartida y de la ayuda a la 
toma de decisión antes de resolver los impor-
tantes desafíos que todavía existen acerca del 
signifi cado y los méritos de estas iniciativas?
Discutimos cuatro desafíos: i) ambigüedad 
e inconsistencia en la defi nición de la deci-
sión médica compartida; ii) variaciones en las 
preferencias de médicos y pacientes sobre la 
decisión médica compartida; iii) el incremento 
en el número y rango de metas defi nidas para 
lograr con la toma de decisión compartida y/o 
la ayuda a la decisión; iv) la carencia de apoyo 
teórico y empírico bien documentado para los 
criterios usados en la evaluación de la calidad 
Abstract
Clinical and research interest in shared 
treatment decision making (STDM) and 
decision aids (DA) evolved in the 1980’s and 
1990’s with an initial focus on patients with 
cancer, and particularly, women with breast 
cancer. This interest has undergone a shift in 
emphasis over time from curiosity about the 
meaning of these concepts and their potential 
to improve patient participation in treatment 
decision making to wide scale endorsement, 
attempts to expand implementation in a variety 
of clinical settings, measurement of multiple 
outcomes at the clinical and public policy 
level, and the development of standardized 
criteria for evaluating DA. In this chapter we 
raise the question: are we moving too fast to 
promote implementation of STDM and DA 
before resolving important challenges that still 
exist about the meaning and merits of these 
initiatives? 
We discuss four such challenges: i) 
ambiguity and inconsistency in the defi nition 
of STDM, ii) variations in patient and physician 
preferences for STDM, iii) the increase in the 
number and range of goals defi ned for STDM 
and /or DA to achieve, and iv) the lack of 
well documented theoretical and empirical 
support for criteria to be used in evaluating 
DA quality, and potentially for purposes of DA 
certifi cation. These fi ndings suggest the need 
for caution, for more thoughtful analysis, and 
additional research on the challenges raised 
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Background
Clinical and research interest in 
shared treatment decision making (STDM) 
and decision aids (DA) evolved in the 
1980’s and 1990’s. The development and 
evaluation of decision aids in cancer 
initially focused on women with breast 
cancer, and to a lesser extent men with 
prostate cancer(1). Over the last 20 years, 
the number of papers and books written 
on STDM and DA has grown dramatically, 
and specifi c topics of research and 
clinical policy interest have undergone 
some shifts in emphasis. For example, 
during the 1990’s STDM was advocated 
as a way to create more informed patients 
and to help involve patients in treatment 
decision making(1,2). Patient involvement 
was seen as a means of achieving ethical 
principles such as patient autonomy and 
patient choice(1-3). Discussions of STDM 
were embedded within the context of the 
physician patient relationship(4-8) and were 
often advocated as a way to counterbalance 
the more common paternalistic approach 
to decision making in which physicians 
played a dominant role(2).
Consistent with this focus, conceptual 
activities undertaken during this time 
centred on various attempts to develop 
conceptual frameworks or ways of thinking 
about the defi ning characteristics of STDM 
as an approach to treatment decision 
making in the medical encounter and 
how this approach differed from other 
approaches commonly talked about and/ 
or used; for example the paternalistic 
approach, the informed approach and the 
physician as perfect agent approach(4-8). 
This type of conceptual work is still being 
undertaken and will be referred to later in 
this paper(9-12).
Empirical research interests refl ected 
these conceptual concerns. Researchers 
studied such issues as patient and physician 
preferences for different approaches to 
treatment decision making in the medical 
encounter(13-17), perceived barriers and 
facilitators to STDM(18) and the impact of 
DA on various outcomes(1,19). DA’s were 
developed initially to help inform patients 
about available treatment options and the 
benefi ts and side effects of each in order 
to better enable them to participate in the 
decision making process(20). The general 
goal of such tools was to improve physician 
patient communication primarily within 
the context of the medical encounter. 
The use of decision aids has now 
spread to other clinical areas beyond 
cancer, in addition, conceptual and 
research interests in STDM have shifted 
in focus. Conceptually, both clinicians 
and researchers still struggle to defi ne the 
meaning of STDM and to defi ne steps 
that physicians can use in implementing 
this approach(9-12). However, despite some 
de las ayudas a la decisión, y potencialmente 
para los propósitos de la certifi cación de la 
ayuda a la decisión. Estos hallazgos sugieren 
la necesidad de precaución, un análisis más 
meditado e investigación adicional en los desa-
fíos mencionados previamente a la promoción 
a gran escala de la decisión compartida y las 
ayudas a la decisión en la práctica clínica ha-
bitual. 
Palabras clave. Decisión médica comparti-
da, ayudas a la decisión. 
above prior to wide scale endorsement of 
STDM and DA in routine clinical practice. 
Key words: Shared treatment decision ma-
king, decision aids. 
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agreement, consensus on the meaning 
of this concept has not been achieved(10) 
and other complex conceptual issues have 
emerged to add to this confusion. For 
example, STDM and DA are now often 
treated as synonymous and interchangeable 
terms in the literature, resulting in further 
ambiguity as to i) the meaning of each, 
ii) their relationship to each other and iii) 
expectations about the goals which each 
is expected to achieve. We discuss these 
issues later in this paper. 
In terms of empirical research, there are 
now broader goals defi ned for STDM and/or 
DA to achieve and more outcome measures 
that researchers are interested in studying(21). 
(These include, for example, a variety of 
psycho-social, clinical, and system level 
health policy goals such as a reduction in 
medical practice variations and health care 
costs. Research interest now focuses, to a 
large extent, on how to promote wide scale 
implementation of STDM and DA in a variety 
of clinical settings, and refl ects a merging 
of scientifi c and advocacy perspectives(22). 
How to quantitatively measure patient 
values for different treatment options 
through the use of DA is another major and 
controversial area of research interest(21,23). 
The use of decision aids as a mechanism to 
gain informed consent from patients is also 
a topic of interest.
The rapid expansion in the development 
of DA has raised concerns about their quality. 
To respond to this issue, an International 
Collaboration led by academic researchers 
have spent several years researching and 
developing a checklist of quality criteria 
to evaluate the development, content and 
effectiveness of DA(24). Underlying this 
initiative is an assumption that there is 
a common and uniform set of evidence 
based quality criteria that can and should 
be used to evaluate different kinds of DA, 
legitimizing those that are judged to meet 
these standards and de-legitimizing those 
that do not. 
In summary, interest in STDM and 
DA has undergone a shift in focus over 
time from: on the one hand, curiosity as 
to what these concepts mean and what 
potential they have for facilitating patient 
involvement in treatment decision making, 
cautious endorsement of each on ethical 
grounds, and evaluation of a limited 
number of goals (or benefi ts) hypothesized 
to result from each: to, on the other hand, 
largely uncritical endorsement of STDM 
and DA, a focus on how to implement this 
approach on as wide a scale as possible, 
measurement of a variety of outcomes 
at the clinical and public policy level, 
and development and application of a 
standardized set of criteria for determining 
what counts and does not count as a high 
quality decision aid.
Objectives
Given the above trends, it is timely to 
raise the question: is the move to endorse 
and promote the implementation of STDM 
and DA being undertaken too quickly? 
Also, should the focus of research interest 
in this topic at this point be weighted 
towards issues of implementation (as 
now seems to be the case) or have we 
moved too fast without addressing some 
important and fundamental unresolved 
issues? We think it is time to step back 
and revisit some of the challenges that 
still exist about the meaning and merits 
of STDM and DA which suggest (at least 
to us) that a more cautionary approach 
is needed in thinking about widespread 
implementation. These challenges relate 
to: i) the defi nition and meaning of STDM; 
ii) variations in patient and physicians 
preferences for STDM, iii) the increase in 
the number and range of goals defi ned for 
STDM and /or DA to achieve, and iv) the 
lack of well documented theoretical and 
empirical support for criteria to evaluate 
DA quality, and potentially for purposes 
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of DA certifi cation. We discuss these 4 
challenges below.
Cautionary tales
i) What is the Meaning of STDM? 
A frequently cited framework for 
defi ning STDM is that by Charles, Gafni 
Whelan et. al.(6,7); who describe i) different 
“pure type” approaches to treatment 
decision making (i.e. paternalistic, shared, 
and informed) as well as “in-between” 
approaches; and ii) different stages of 
decision making (information exchange, 
deliberation and making the decision. 
The framework then defi nes the role 
expectations of physicians and patients in 
the acute care context (specifi cally, early 
stage breast cancer) by stage of decision 
making for the different approaches to 
decision making. In other words, the 
framework attempts to defi ne specifi c 
behaviours for both patients and physicians 
that would characterize a “pure” informed 
versus shared versus paternalistic approach 
to treatment decision making. The authors 
recognize that these “pure” approaches are 
unlikely to be found in reality and that 
most physician /patient interactions will 
lie somewhere in -between these pure 
types. Hence, as the authors imply, those 
who advocate that a STDM approach be 
implemented as routine practice may be 
aiming for an approach that is, in reality, 
unrealistic to start with, since i) actual roles 
that physicians and patients play in the 
decision making process are dynamic and 
can change even within a single encounter 
and ii) participation of both physicians 
and patients in decision making may not 
conform to the “pure” type behavioural 
expectations of any single decision making 
approach.
Despite the fi nding that the Charles et. 
al. framework for defi ning the meaning 
of STDM(6,7) is the most commonly cited 
in the literature(10), there is no consensus 
that any one framework captures the full 
meaning of this concept(9,25). In so far as 
there is still disagreement on the meaning 
of STDM, attempts to measure its impact 
and to promote its implementation remain 
problematic because the concept itself 
is open to different interpretations. Also, 
variable coding schemes and measurements 
of STDM defi nitions make it diffi cult to 
compare results across studies(25).
As well, recent conceptual and 
empirical work have suggested that there 
are other dimensions to the concept of 
STDM which have not typically been 
discussed in the literature but which require 
further attention. For example, O’Brien, 
2009 (26) found in her study that several 
women with early stage breast cancer in 
Ontario, Canada reported sharing in the 
TDM process with their doctors, even 
though they reported not taking an active 
role in making the fi nal treatment choice. 
This suggests that other factors play an 
important role in patient’s perceptions of 
involvement. Similarly, Entwistle (11) has 
discussed the importance of the relational 
aspects of the physician patient relationship 
to patient perceptions of involvement in 
the decision making process. 
These fi nding suggest that when we 
talk about STDM we need to differentiate 
between (at least) two different ways 
of conceptualizing and measuring this 
phenomenon: STDM as i) a set of role 
expectations identifi ed for patients 
and physicians which are thought to 
characterize a STDM treatment approach 
and which can be measured either through 
observation or self reports (e.g. the Charles, 
Gafni, Whelan et. al., framework (6,7) or ii) 
a subjective feeling state experienced by 
patients who express perceptions of being 
involved in the treatment decision making 
process, even if they do not actually play 
an active role in making the decision. 
These are two different ways of thinking 
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about STDM and it is not clear if and how 
these can be integrated(11), or which of 
these ways of thinking (or both) is being 
advocated by those promoting STDM. 
Unless this issue is clarifi ed, instructing 
physicians on how to implement a STDM 
approach will be problematic. 
Similarly when evaluating outcomes 
of STDM, we need to ask whether it is 
more important to explore the impact of 
patients’ observed and/or reported level 
of behavorial involvement in treatment 
decision making or to explore patient 
perceptions of involvement, no matter how 
these perceptions come about. We still do 
not fully understand the range of factors that 
trigger patients to feel involved in treatment 
decision making or even what involvement 
might mean to different patients. Thinking 
about different ways of conceptualizing 
the meaning of STDM and its implications 
is an important activity because the current 
emphasis on implementation assumes 
that we already know in a defi nitive way 
what STDM means and that its meaning 
is universal, constant and unproblematic. 
This is clearly not the case.
Not only are there various defi nitions 
of STDM, there are also difference in 
emphasis within a single conceptual 
framework defi ning the meaning of 
STDM in terms of the steps involved for 
physicians and patients in implementing 
this approach in different clinical practice 
settings. For example, using the Charles et 
al framework of STDM as a starting point, 
various clinical researchers have described 
modifi cations needed to implement this 
framework in different clinical areas such 
as diabetes(27) and general practice(28), in 
contrast to cancer care which was the 
original acute care clinical context within 
which this framework was developed. 
Hence, identifying the defi ning the steps 
of a STDM approach for purposes of 
implementation is not a “one size fi ts 
all” endeavor and requires sensitivity to 
the specifi c context of different practice 
settings. 
STDM has typically been discussed and 
described as an approach to TDM between 
doctor and patient in the clinical encounter. 
Increasingly, however, patients will bring 
a signifi cant other with them to the 
encounter. This transforms the interaction 
from a dyad to a triad and greatly expands 
the interactional possibilities among the 
three participants. With three (or more) 
participants, for example, coalitions of 
various types can be formed between 
two participants who favour a particular 
treatment option in opposition to the views 
of the third participant.
To date, there have been few empirical 
studies or conceptual frameworks exploring 
this three way (or more) participation in TDM 
and attempting to describe what counts as 
STDM in this broader interactional context. 
Hence, the ways in which current research 
studies conceptualize and measure STDM 
in the clinical encounter may not accord 
with the realities of clinical practice in 
which the patient’s signifi cant other(s) may 
play a variety of roles (e.g. listening to 
and/or recording information presented by 
the physician, asking questions, providing 
information about the patient to the 
physician, participating in deliberations 
about the treatment options presented 
etc). More conceptual and empirical work 
is needed to help defi ne and describe what 
STDM means in this broader interactional 
context. 
In summary, there are several important 
conceptual issues that still require 
attention in order to be able to clearly 
and consistently defi ne what we mean 
by STDM. Until we know what we mean 
by this concept, trying to implement 
STDM as part of routine practice remains 
problematic.
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ii) Do Variations in Patient and Physician 
Preferences for STDM Exist?
STDM is increasingly advocated as 
a kind of ideal way to make treatment 
decisions. However, empirical studies 
show that some patients prefer that their 
physician make the treatment decision(2,3), 
and there is nothing inherently wrong with 
this preference. Also some physicians may 
not feel comfortable sharing the decision 
making process (29) and both parties 
(physicians and patients) must agree to 
this approach if it is to be implemented 
voluntarily in any given encounter. Some 
patients may prefer to make the decision on 
their own or with family and friends rather 
than with the physician (the informed 
approach), and some patients may prefer an 
in-between approach. Interestingly, there 
has been less research attention paid to the 
informed approach to treatment decision 
making (compared with STDM) and to 
exploring the positive and negative impacts 
of the former on a variety of outcomes This 
may be because there is some confusion 
in the literature as to whether these two 
approaches are one and the same or 
different. (See Charles, Gafni &, Whelan(6,7) 
for a discussion of their differences). 
The alleged merits of STDM and DA 
have become so widely endorsed that sev-
eral United State’s state governments are 
considering or have passed legislation to 
promote further research, demonstration 
projects and more widespread imple-
mentation of these initiatives(30). One state 
(Minnesota) considered (but ultimately re-
jected) passing legislation that would have 
required patients enrolled in public pro-
grams to participate in a patient –centred 
decision making processes before provid-
ers could be reimbursed for surgeries for a 
number of conditions(31). Even the sugges-
tion to mandate implementation of STDM 
seems problematic in light of both defi ni-
tional differences in what this term actu-
ally means and how to implement this ap-
proach, and in light of research evidence 
suggesting that there are differences in 
patient and physician preferences for in-
volvement in treatment decision making. 
Given this fi nding and the possibility that 
patient preferences might be formed and 
even change several times during a single 
medical encounter, advocating STDM for 
widespread routine use in clinical practice 
seems misguided, whatever good inten-
tions lie behind this endorsement. 
Also the meaning and appropriateness 
of STDM in different cultural contexts is 
still a relatively under researched area 
and little is known about the fi t between 
shared approaches to treatment decision 
making, including the use of decision aids, 
and different cultural contexts. Decision 
aids embody a number of cultural 
assumptions which are often not made 
explicit. For example, decision aids are 
fi rmly embedded in a biological model 
of illness, an evidence-based medicine 
paradigm, and medical concepts of risk. 
These beliefs refl ect a purely ‘‘technical’’ 
or “‘clinical’’ approach to decision-
making and downplay the infl uence and 
signifi cance of other factors, including 
cultural beliefs(32). 
The use of decision aids also refl ects a 
cultural emphasis on the autonomy of the 
individual in decision making as opposed 
to a broader social framework within which 
to view this process(33,34). These common 
features of decision aids are not surprising, 
given the clinical and research contexts 
in which they have been developed. But 
we wonder to what extent such tools are 
appropriate for patients from different 
cultural groups and how sensitive such 
tools are to the values of different cultural 
groups. We also wonder to what extent 
these cultural issues have been addressed 
in either the research development phase 
of decision aids or their implementation 
and evaluation. Even such basic issues 
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as the range of treatments considered 
appropriate to include as options and the 
type of information considered relevant to 
evaluate options may vary depending on 
cultural beliefs. 
iii) What Outcomes Can and Should 
STDM and /or DA be Expected to 
Achieve and What is the Relationship 
Between Them?
Since the early 1990’s decision aids 
have been advocated as a tool to help 
physicians involve patients in the treatment 
decision making process, i.e., to promote 
and facilitate STDM and to create more 
informed patients. Over time, however, the 
conceptual link tying the use of decision 
aids to the facilitation of STDM has 
become more blurred. In some cases, the 
term decision aid is now talked about as if 
it is synonymous and interchangeable with 
the term STDM, and similar outcomes tend 
to be measured. In other cases, interest 
in the impact of decision aids on patient 
outcomes is seen as an important research 
topic in and of itself overshadowing the 
question of what role decision aids can 
play in different approaches to treatment 
decision making. In fact, some goals have 
been defi ned for decision aids that go well 
beyond a role in promoting STDM, as we 
will discuss below. 
Like the concept of STDM, defi nitions 
of the term decision aids vary, with 
some defi nitions focusing on the role of 
decision aids in conveying information 
to patients on the benefi ts and risks of 
various treatment options(35) and other 
defi nitions focusing on the role of 
decision aids in improving the quality of 
decisions, with decision quality defi ned 
as “the extent to which patients choose 
and /or receive health care interventions 
that are congruent with their informed 
and considered values”(36). Whether 
decision aids should be expected to elicit 
and measure patient preferences, and if 
so, how, is a controversial topic and we 
have discussed this issue in more detail 
elsewhere Charles, Gafni & Whelan(21).
The number and range of outcomes 
that decision aids are expected to achieve 
has also grown over the last decade, and 
are somewhat controversial(21,37). These 
measures fall into different conceptual 
categories. One major category of 
outcomes relates to information transfer 
and includes such measures as the extent 
of patient knowledge and understanding of 
treatment risks and benefi ts(20,38-40). Another 
category of outcomes relates to the impact 
of decision aids on the decision making 
process and on the treatment decision, 
including, the extent to which patients 
want to participate in the process, the 
specifi c decision made, satisfaction with 
the decision making process and with the 
decision(41,42). A third category of outcomes 
relates to the psychological impact of 
decision aids on, for example decisional 
burden, decisional confl ict and decision 
regret(43-46). A fourth category of outcomes 
relates to health status and includes 
the impact of decision aids on various 
measures of health status and quality of 
life(47-51). More recently several systematic 
reviews of DA Impact(35,52). Finally the 
effects of decision aids on overall health-
care system costs have been measured by 
examining the global fi nancial impact of 
changes in individual patient’s treatment 
choices (either to more expensive or less 
expensive treatments) after using some 
form of decision aid(37). The fi nancial 
cost of actually using a decision aid in 
the medical encounter in terms of time 
required to administer the instrument has 
also been of interest(53).
Our concern with the above list is that 
all of these outcomes are being studied, 
not necessarily because they refl ect our 
best thinking about what are the most 
appropriate goals that decision aids 
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can be expected to achieve, but rather 
because these are the outcomes that many 
researchers claim they can measure. We 
feel that the rationale for the selection of 
specifi c decision aid goals needs to be 
thought through prior to the selection of 
specifi c outcome measures; the selection 
of goals should drive what is measured and 
not the other way around. Yet empirical 
studies evaluating the impact of decision 
aids often report on specifi c outcome 
measures without linking these to any 
specifi c goals defi ned for the decision 
aid they are studying or exploring what 
mechanisms are hypothesized to link a 
particular decision aid design feature to a 
particular outcome. This makes replication 
of the potentially desirable feature in future 
decision aids problematic. 
In the Charles, Gafni & Whelan(6,7) 
conceptual framework defi ning STDM, DA 
are seen as a tool to convey information to 
patients about treatment options and their 
benefi ts and risks (as part of the information 
exchange stage of the decision making 
process) and not as a tool to achieve other 
broader goals(6,7). Even in relation to this 
one goal, there is still important research 
that needs to be undertaken to explore i) 
the extent to which patients understand the 
information as intended (rather than simply 
recall the numbers presented) and ii) the 
extent to which this information is made 
personally meaningful to the individual 
patient in his/her decision making process 
(i.e. what does this mean for me?). 
Recently in the United States emphasis 
has been placed on promoting STDM as 
a means of achieving two system level 
goals: reducing practice variations and 
reducing health care costs(22). These goals 
would only be met if patients consistently 
chose the same treatment option and the 
one that is less expensive than the others 
offered. But it is not clear why the practice 
of STDM is seen as an appropriate policy 
instrument to achieve this goal. (The 
question of whether these are appropriate 
goals is another issue). Underlying the 
concept of STDM is the concept of patient 
choice. If the policy objective is to reduce 
practice variations and health care costs, 
then why offer choice in the fi rst place? 
This policy initiative seems to refl ect the 
cooptation of a popular patient centred 
movement (STDM) originally intended to 
promote patient choice (regardless of the 
cost implications of patients’ choices), in 
order to achieve unpopular health care 
system level goals, whose very success, 
ironically, depends on the unrealistic 
assumption that patients will always 
voluntarily restrict their treatment choice 
to the less costly treatment alternative. (See 
Charles, Gafni, Whelan et. al., 2005(21) for 
a detailed discussion of this assumption).
iv) What Criteria Should We Use to 
Evaluate the Development, Content and 
Effectiveness of Decision Aids? 
Over the last decade, the growth in 
the number of DAs has been dramatic. 
According to Elwyn, O’Connor & Stacey 
et. al.(24), by 1999, approximately 15 
patient DAs had been developed in 
academic institutions but by 1996, more 
than 500 existed, produced largely by 
a mix of not for profi t and commercial 
organizations”(24). The design of a DA (i.e. 
the way in which information on treatment 
options, their potential benefi ts and side 
effects is communicated to a patient) 
can have a marked impact on a patient’s 
understanding of treatment options and 
on her treatment decision. However, 
until recently, there was no consensus 
on the most credible criteria by which 
to evaluate these tools. To help fi ll this 
gap, an International Patient Decision 
Aids Standards (IPDAS) Collaboration was 
developed(54).
The Collaboration consists of an 
international group of researchers, patients, 
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health practitioners and policy makers. 
Over several years, the Collaboration has 
worked to develop a criteria based checklist 
for evaluating “the development, content 
and effectiveness of decision aids”(24,55). 
An instrument derived from this criteria-
based checklist and designed to measure 
the quality of patient DAs (the IPDASi) was 
also developed by this Collaboration and 
is currently being offered for use in DA 
assessments(55,56).
 While the intent of this International 
Collaboration was positive, i.e., to bring 
some standardization, coherence and 
a certain threshold of quality to the 
development and evaluation of decision 
aids, the results of the development 
process, the list of quality criteria can be 
challenged. (The full checklist of specifi c 
domains covered and specifi c criteria 
within these can be found at: http://ipdas.
ohri.ca/resources.html) 
In a recent review article McDonald, 
Charles & Gafni(57) explored the available 
evidence and theoretical (conceptual) 
support used by members of the IPDAS 
Collaboration to justify the inclusion of the 
specifi c quality criteria found in the domain 
on presenting to patients probability 
information on treatment benefi ts and risks. 
McDonald et. al., found substantial gaps in 
the amount of empirical and/or theoretical 
support identifi ed to justify inclusion in the 
checklist of these criteria. 
Pressure is growing to use these 
criteria to evaluate decision aids and, 
on this basis, to differentiate between 
those that are found to meet a threshold 
quality standard from those that are not, 
and to offer certifi cation to those decision 
aids meeting this threshold. This sense 
of urgency to implement a universal set 
of standards risks premature closure on 
further discussion about the theoretical 
and scientifi c justifi cation for these criteria 
in the fi rst place. Once these criteria are 
widely used as a gold standard to evaluate 
decision aids, they will have a powerful 
role in shaping the future development and 
content of decision aids internationally, as 
well as in legitimizing some forms of DA 
and delegitimizing others. 
Because of these implications, stronger 
empirical and theoretical support is needed 
in order to justify promoting or, even more 
strongly, mandating the use of such criteria 
for evaluating and certifying decision 
aid quality. In addition, whether one set 
of standardized criteria is suffi cient for 
evaluating the development, content and 
impact of a wide variety of decision aids 
internationally, or whether a more tailored 
approach to meet local clinical and cultural 
contexts may be more appropriate in some 
situations needs to be further explored. 
Discussion
Breast cancer support groups and 
women with breast cancer were early 
advocates of increasing the opportunities 
for patients to participate in treatment 
decision making within the context of the 
medical encounter. In response, researchers 
began to try to defi ne the meaning of a 
shared approach to treatment making 
that would provide greater involvement 
for patients and to develop tools such as 
DA to facilitate use of this approach in 
clinical practice. Now, it seems that STDM 
and DA are advocated for a wide variety 
of clinical contexts and are promoted as 
being able to solve multiple problems 
above and beyond communication issues 
found in the medical encounter. In recent 
years, research and advocacy interests 
have merged such that some researchers 
in this fi eld are also strong advocates for 
implementing STDM and/ or DA on a 
wider basis and are involved in activities 
to further this end.
We think it is premature to advocate 
and support wide scale implementation of 
STDM and DA in order to achieve broad 
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system level goals that they were never 
intended to achieve. STDM approaches 
and DA were developed in the context of 
the physician patient encounter to improve 
physician patient communication. We think 
there is a need to refocus our attention 
on this original context and recognize 
that STDM is not for everyone. Rather, 
patients and physicians can decide to use 
this approach but they have to understand 
fi rst what it is, and they have to voluntarily 
agree that this approach is agreeable to 
both parties in any given clinical encounter. 
Moreover, there is no one formula that can 
be taught to physicians for implementing 
STDM – no prescription as to how to do it. 
While the Charles et al framework describes 
necessary steps for both physicians and 
patients to follow in a shared process, the 
authors recognize that implementation of 
these steps can take a variety of forms, 
depending on the individuals involved and 
the particular clinical context. 
Charles et al.(7) also recognize that 
decision making is a dynamic process 
which can evolve and change even during 
a single encounter. This implies that 
physicians need to be fl exible and ready 
to change their approach if the patient in 
front of them expresses a desire to become 
more or less involved in decision making 
as the encounter progresses. (For examples 
of how this might occur, see Charles, Gafni 
& Whelan(7). All of this suggests that trying 
to promote implementation of STDM into 
routine practice as an unquestioned good 
at this time may cause more harm than 
good. If STDM and DA fail to achieve all 
the goals set for them, these concepts and/ 
or their premature implementation will be 
blamed, risking repudiation of the basic 
ideas themselves. 
As the number and range of goals 
defi ned for DA expands, the perceived 
need for criteria to assess the quality of 
DA design, content and implementation 
has also grown. But the promotion and 
implementation of the internationally 
developed IPDAS standards for assessing 
DA and for possible certifi cation also seems 
premature. First, the goals defi ned for DA are 
expanding and there is as yet no consensus 
on what these should be, so that developers 
of criteria face a constantly moving target. 
Second, stronger theoretical and empirical 
support for the suggested quality criteria 
should be established before endorsement 
of these for quality improvement and 
possible certifi cation purposes. Third, it 
is not clear that a single uniform set of 
standards can be applied to assess the 
quality of different types of decisions aids in 
different clinical and cultural contexts and 
with potentially different goals underlying 
their development. 
 In conclusion, we suggest the need 
for caution, for more thoughtful analysis, 
and additional research on the challenges 
raised above prior to endorsement of 
STDM and DA in routine practice. This 
would involve a systematic, step by step 
attempt to address current unresolved 
issues raised in this paper in order to 
make implementation more feasible in 
clinical contexts where both patients and 
physicians freely choose this approach to 
making treatment decisions. 
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